Suivre
Abonner UCB Pharma

UCB Pharma

Filtre
  • 25.02.2021 – 07:00

    UCB Full Year Report 2020: UCB - sustaining growth, now and into the future

    Brussels (ots/PRNewswire) - · Revenue increased to EUR 5.3 billion (+9%, +8% CER[1]) net sales to EUR 5.1 billion (+8%, +7% CER) · Underlying profitability (adj. EBITDA[2]) was EUR 1.4 billion (+1%, -4% CER) or 27% of revenue · R&D update: bimekizumab filed with FDA and EMA for psoriasis; timelines for late stage pipeline confirmed - despite pandemic · Financial ...

  • 23.02.2021 – 07:00

    UCB and Microsoft Expand Collaboration to Accelerate Drug Discovery and Development

    Brussels and Atlanta (ots/PRNewswire) - - Through this collaboration with Microsoft, UCB seeks to discover and develop medicines faster for people living with severe diseases in immunology and neurology - Microsoft will provide AI technology and applied scientists to work alongside UCB's scientists and data specialists, aiming to allow UCB to discover new correlations ...

  • 27.07.2020 – 07:10

    UCB Half Year Report 2020

    Brussels (ots/PRNewswire) - - UCB's resilient product portfolio drives continued company growth - Revenue increased to EUR 2.6 billion and net sales to EUR 2.5 billion, both +12%, +9% CER or +10% at CER and adjusted for divestitures respectively - Underlying profitability (adj. EBITDA) was EUR 783 million (+8%, 0% CER) or a ratio of 30% - Ra Pharma acquisition closed early April, Engage Therapeutics acquired in June, co-promotion agreement for Cimzia® with Ferring in July - ...

  • 10.04.2020 – 15:00

    UCB's General Meeting of Shareholders

    Brussels (ots/PRNewswire) - - Update on attendance and voting instructions relating to UCB's General Meeting of 30 April 2020 - Implementation of Royal Decree n°4 of 9 April 2020 on various provisions regarding the legislation on co-ownership and companies and associations, in the framework of the fight against the Covid-19 pandemic - No physical presence at General Meeting allowed and votes can only be submitted by ...